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Summary The c-Ha-ras gene was analysed by Southern blot hybridisation in 67 specimens of lymph node
metastases and in 25 specimens of primary tumours obtained from 85 untreated patients with head and neck
squamous cell carcinoma. The loss of one c-Ha-ras allele was observed in 10/46 (22%) tumours from
heterozygous patients for this locus. Different genes, located as the c-Ha-ras gene on the short arm of
chromosome 11, were also found to be deleted suggesting that the deletion of other genes could play a role in
aggressiveness of head and neck carcinomas. Using polymerase chain reaction, mutation at codon 12 was
detected in only 2/54 (3.8%) tumours but no mutation involving codon 61 was found. Neither gene
amplification nor gene rearrangement could be observed. Total RNA was prepared from 79 of these tumour
specimens and analysed by Northern and slot blot hybridisation. A 1.2 kb c-Ha-ras transcript band was
detected in all the RNA preparations. Relatively high c-Ha-ras transcript levels were found in 18% of lymph
node metastases and in 21% of primary tumours, indicating no significant differences between these cancers.
Moreover, the c-Ha-ras mRNA levels were not significantly greater in the primary tumours than in the normal
mucosae in 10/12 cases for which both tissues were analysed. These data indicate that c-Ha-ras gene does not
seem to be strongly involved in head and neck carcinomas at that advanced stage of the disease, as this was
previously reported for earlier clinical stages.
It is now well established that genetic alterations are impli-
cated in the biological deregulation of cancer cells and that
the cellular oncogenes are involved in the cancer process
(Bishop, 1987; Merkel & McGuire, 1988; Nordenskjold &
Cavenee, 1988). Among those cellular oncogenes, the ras
genes were thought to play an important role and many
studies were initiated to detect alterations and aberrant ex-
pression of these genes. Somatic mutations, resulting in the
substitution of a single base at particular positions in the
gene locus were found to be responsible for oncogenic
activity by transfection assay, in about 15% of cancers (Bar-
bacid, 1988). Recently, using more sensitive methods, high
rates of mutation affecting the c-Ki-ras gene were detected in
DNA from pancreas and colon carcinomas (Bos et al., 1987;
Forrester et al., 1987; Almoguera et al., 1988; Bos, 1989). In
colon tissues the c-Ki-ras mutations were even found in the
precancerous lesions which were assumed to progress in
invasive carcinomas. Mutations of the ras gene were also
found in thyroid adenomas and carcinomas (Lemoine et al.,
1988; Suarez et al., 1988). C-Ha-ras mutation at codon 12
was shown to be associated with cervical cancers of poor
prognosis (Riou et al., 1988). A c-Ha-ras restriction fragment
length polymorphism (RFLP) (Capon et al., 1983) linked to
susceptibility of individuals to cancers was reported (Kron-
tiris et al., 1985) and deletions of the c-Ha-ras locus were
observed in a variety of human cancers (Nordenskjold &
Cavenee, 1988; Riou et al., 1988; Sheng et al., 1988). Other
alterations of the ras gene consisting of amplification or
rearrangement were more rarely found in human tumours
(Barbacid, 1988). On the contrary, studies on the expression
of ras genes indicated that high levels of ras-specific
messenger RNA and ras p21 protein were associated with
tumour progression in human cancers of different origins
(Viola et al., 1986; Clair et al., 1987). However studies have
shown the presence of high levels of ras transcripts or pro-
teins in normal tissues (Furth et al., 1987; Kerr et al., 1985)
while others have reported that high levels of these gene
transcripts or protein were not necessarily related to tumour
progression (Spandidos & Kerr, 1984; Gallick et al., 1985;
Chesa et al., 1987).
In this study w- have analysed the c-Ha-ras-l for allelic
deletion, mutation, amplification and expression in the same
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specimens of a large series of lymph node metastases from
patients with head and neck squamous cell carcinomas. Our
aim was to determine whether the c-Ha-ras proto-oncogene
by alteration of its structure and/or overexpression plays also
a role in the progression of these cancers known to be of
poor prognosis.
Materials and methods
Carcinomas and control specimens
Ninety-two specimens of head and neck squamous cell car-
cinoma of different locations were obtained by surgical
excision from 85 untreated patients (Table I); 25 samples
were primary tumours and 67 samples were lymph node
metastases. We could obtain both primary tumours and
lymph node metastases from 7 patients and primary tumours
and normal mucosa from 14 other patients. In each case,
normal mucosa was cut off distantly from the tumour. His-
topathological examination was performed on all the tissue
specimens (Figure la, b and c). Carcinomas were of
squamous cell histological type. A large marjority of these
carcinomas were well differentiated. Lymphocytes were
obtained from 65 healthy donors and 15 patients. The lym-
phocytes were fractionated in a Ficoll-Hypaque gradient. All
the tissue and cell samples were immediately stored in liquid
nitrogen.
Isolation ofDNA and RNA
DNA and RNA were prepared from the same tissue samples
corresponding to about 50-200 mg of fresh tissue. Frozen
tissues were ground in liquid nitrogen and nucleic acids
extracted by the guanidinium-thiocyanate method. DNA and
RNA were fractionated by centrifugation in a CsCl gradient
(Maniatis et al., 1982; Terrier et al., 1988). Nucleic acids were
also prepared from EJ human cancer cell line. EJ cells
originated from a bladder carcinoma with transitional cells
exhibiting on the c-Ha-ras gene a point mutation at codon 12
involving a transversion G T.
Southern blots
DNA preparations (5 or 10jLg) were incubated with HpaII-
MspI enzymes to analyse c-Ha-ras RFLP and allele loss and
with Sacd enzyme to analyse the structure of the locus.
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Southern blot hybridisations using the different probes were
performed. Other genes located on the short arm of
chromosome 11 were also studied for allelic loss. Different
restriction enzymes and probes were used as noted in the
legend of Figure 2.
Northern blots
Denatured total RNA samples (10 g per well) fractionated
on a 1.2% formaldehyde agarose gel and transferred to a
Hybond C extra filter were analysed by Northern blot hyb-
ridisation as previously described (Maniatis et al., 1982). The
quality and the quantity of total RNA were tested by a
preliminary electrophoresis in a non-denaturing 1.2%
agarose mini-gel. The filters were exposed at - 70°C to
Kodak XAR 5 films for various periods of times.
a
Figure 1 Histological sections. Normal mucosa a, and squamous
cell carcinoma b, were obtained from larynx by surgery. Car-
cinoma was composed of typically well differentiated squamous
cells. Lymph node metastatic tumour exhibiting extracapsular
rupture c, arrow. (Hematoxylin-eosin stain. a, bx 136; c, x 21.25).
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Figure 2 Schematic representation of the 6.6 kb BamHI DNA
fragment carrying the human c-Ha-rasI gene obtained from EJ
cells. The black boxes represent the 4 exons and the hatched box,
the region ofvariable tandem repetition (VTR). The 2.5 kb Sacl-
BamHl DNA fragment (probe 1) was used to detect RFLP and
gene deletions, the 2.91kb Sacl-SacI DNA fragment (probe 2)
encompassing the 4 exons was used to detect amplification and
expression of the gene (B, BamHl and S, Sacl restriction sites).
Slot blots
Preparations of total RNA were applied to nitrocellulose
filters (BA 85) using a slot blot apparatus (Schleicher &
Schuell). Total RNA from EJ cell line was used to measure
the levels ofc-Ha-ras mRNA. Transcript level in this cell line
was stable and arbitrarily considered as 1 unit. Transcript
level was determined by densitometer scanning of the
autoradiographic bands (Chromoscan 3, Joyce Loebl). To
provide a control for the amount of RNA on the filters, the
c-Ha-ras gene signal was removed and the same filters rehyb-
ridised with an actin probe.
Detection ofmutation by polymerase chain reaction (PCR)
We have amplified sequences spanning 63-128 base pairs
across codons 12, 13, and 61 of ras (Verlaan-de Vries et al.,
1986). Amplification was carried out as described by Saiki et
al. (1985) using Thermus aquaticus DNA polymerase (Perkin-
Elmer Cetus). All the oligonucleotides used in our laboratory
were synthesised by the solid phase triester method. The 5'
ends of oligomers were labelled with T4 polynucleotide
kinase (Maniatis et al., 1982). Aliquots (2 tLI) of the PCR
mixture were spotted to a nylon filter (Gelman) and hy-
bridised to a panel of 20 mers synthetic oligonucleotide
probes. Hybridisation and washing of filters were performed
in a 3 M tetramethylammonium chloride salt solution
(Verlaan-de Vries et al., 1986).
Probes
Two c-Ha-ras probes were used, the 2.5 kilobase pairs (kb)
BamH1-Sacd DNA fragment (probe 1) encompassing the
Variable Tandem Repetitive (VTR) region (Capon et al.,
1983) and the 2.9 kb SacI-SacI DNA fragment encompassing
the c-Ha-ras coding exons (probe 2). These probes were
obtained from the 6.6 kb c-Ha-ras-l gene of EJ cells. Probes
used as markers on chromosome 11 were: D I S12 from clone
pADJ762 (Barker et al., 1984); HBBC (yG and 'A of the ,B
globin cluster) from clone JW151 (Antonarakis et al., 1982);
PTH (human parathyroid hormone) from clone pPTH 2.5
(Vasicek et al., 1983); CALC (calcitonin) from clone phTB3
(Craig et al., 1982); CAT (catalase) from clone pCAT41
(Korneluk et al., 1984).
Results
Characteristics of head and neck carcinomas are presented in
Table I. A large majority of the carcinomas which were
analysed, were of poor prognosis since patients had lymph
node involvement with extracapsular rupture, one of the
most powerful indicator of prognosis in these types of cancer
(Figure lc). RFLP was analysed in DNA preparations from
carcinomas and from lymphocytes of healthy blood donors. A
RFLP for BamHI or MspI (Capon et al., 1983; Krontiris et
al., 1985) was found to occur in a region of variable tandem
repetition (VTR) located at the 3' end of the c-Ha-ras locus
(Figure 2). After Southern blot hybridisation using the c-Ha-
ras-I VTR probe (probe 1, Figure 2), several classes of allelic
restriction fragments were observed, some of them were fre-
quently detected while others rarely found (Krontiris et al.,
1985). Single or 2 DNA fragments were revealed in cancer
DNA preparations from homozygous and heterozygous
patients respectively. Figure 3A shows representative patterns
of hybridisation from tumour DNAs. Similar patterns were
obtained from DNAs of unaffected population (data not
shown). The size and the frequency of the different alleles are
presented in Table II. The rare alleles occurred with similar
combined frequencies in head and neck patients (7%) and in
normal individuals (6.5%). As expected, identical c-Ha-ras-1
VTR alleles were detected in DNAs from tumours and lym-
phocytes or normal mucosae obtained from the same patients.
Heterozygosity for this allele was found in 46 tumours and
the loss of I allele was observed in the tumour samples from
10 (22%) of these heterozygous patients (Figure 3B).
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Table I Characteristics of squamous cell head and neck carcinomas and tissues
No. ofpatients
Site of Total No. of node with at least No. of samples analyse?
the primary no. of positive one node with Primary Node Normal
tumour patients patients extracapsular rupture tumour metastasis mucosaf
Hypopharynx" 22 22 20 6 19 4
Oral cavityb 21 21 20 5 18 1
Larynxc 18 14 14 5 14 5
Oropharynxc 14 13 12 4 11 3
Sinus and hard 5 1 1 4 1 1
palate
Unknownd 5 5 5 1g 4
Total 85 76 72 25 67 14
abcBoth primary tumour and metastasis from 3", 2b and Ic patients were analysed. dLymphadenopathy with unknown site
of the primary tumour. eDNA from the 92 tumour samples were analysed whereas RNA from 79 of these samples were
analysed. 'Both normal mucosa and primary tumour from 14 patients were analysed. gThe sample quoted with primary
tumour was a tumoral mass of unknown origin.
a b c d e f g h i j
A
B
Li Cal N2 Ca2 N3 Ca3 L4 Ca4 N5 Ca5
kb
1_2.62.4
-1.6
-1.2
0-- 1.95
kb
-2.6
_1.6
_1.2
-1.1
Figure 3 Southern blot analysis of c-Ha-ras-I restriction frag-
ment length polymorphism in head and neck squamous cell
carcinomas and normal cells from patients (normal mucosa, N;
lymphocytes, L). DNA samples (5jAg) were digested with HpaII-
MspI, electrophoresed in 2% agarose gel and hybridised with the
c-Ha-ras-l-VTR probe (probe 1 of Figure 2). DNA with similar-
sized alleles were re-electrophoresed in the same gel in separated
wells and in the same well. A, head and neck carcinomas. B, pairs
L-Ca (carcinoma) and N-Ca from the same patients. Note the
loss of I allele in Cal, Ca2 and Ca3. A faint hybridisation band to
the deleted band probably due to the presence of normal cells in
tumours was observed in Cal and Ca3.
Table II C-Ha-ras allele frequencies in head and neck carcinomas
and normal lymphocytes
Allele frequencies (%)
Lymphocytes of
Allek size healthy donors Carcinomas
(kb) (65)a (71))
Common alleles
1.1 66.0 54.9
1.6 14.5 12.7
2.2 6.5 9.9
2.6 6.5 15.5
Total 93.5 93.0
Rare alleles
0.95 to 2.8 6.5 7.0
'In parentheses the number of samples analysed.
Several genes located in the vicinity of the c-Ha-ras locus
on the short arm of chromosome 11 wf re also analysed to
determine the extension of chromosome deletion. An allelic
loss pattern after Southern blot hybridisation (Figure 4) and
a schematic representation of the deleted genes (Figure 5) are
presented. The allelic deletions for different loci on
chromosome 1 'p were observed in 4 of the 11 head and neck
carcinomas analysed. One HBBC allele belonging to the 0
globin cluster was lost in these 4 carcinomas together with 1
c-Ha-ras allele in 3 carcinomas and with 1 calcitonin allele in
the other carcinoma.
The presence of mutation at positions 12 and 61 on the
c-Ha-ras locus was investigated in 54 carcinoma specimens
using the PCR technique and hybridisation with synthesised
specific probes. A mutation affecting the codon 12 as in the
EJ cell lines was observed in only 2 carcinomas and not
detected in the lymphocyte specimens. The same transversion
G T was observed in the 2 cases of mutated c-Ha-ras genes
(Figure 6). No mutation was detected at position 61. The
presence ofmutation at positions 12, 13 and 61 on the Ki-ras
gene and of mutation at positions 12 and 61 on the N-ras
gene was also investigated in 28 carcinoma samples. No
mutation could be evidenced (data not shown). DNA
preparations, after digestion with Sacl, were analysed by
Southern blot hybridisation with the probe 2 (Figure 2)
encompassing the 4 c-Ha-ras exons. As expected a 2.9 kb
DNA band was observed in all the DNA preparations.
Neither gene amplification nor gross gene rearrangement
were found in carcinomas (Figure 7).
The total RNA was prepared from 79 specimens of these
carcinomas and from 12 specimens of normal mucosa. RNA
preparations were analysed by Northern and slot blot hy-
bridisation using the c-Ha-ras-l gene probe 2 of Figure 2. As
usually observed in human tissues, a 1.2 kb transcript band
was detected in all RNA preparations. A representative
Northern blot was shown in Figure 7. Blots were deshy-
bridised then rehybridised with the actin probe which was
assumed to be equally expressed in cancers. The levels of
c-Ha-ras gene transcripts were determined by densitometric
analysis of autoradiograms from slot blots and normalised
against actin values (Figure 8). Relative levels were evaluated
by comparison to c-Ha-ras transcript level obtained in EJ
cells. Lymph node metastases and primary tumours were
independently grouped according to their relative c-Ha-ras
mRNA levels (Figure 9). The mean values (in arbitrary units
± standard deviation) were equal to 0.8 (± 0.9) in metastases
and 0.9 (± 0.6) in primary tumours. The differences were not
found to be significant (Student Fisher test P = 0.4). The
c-Ha-ras mRNA levels found in individual primary tumours
and normal mucosae node metastases are presented in Figure
10. In only 2 of 12 cases, the c-Ha-ras transcript level was
found to be significantly higher in tumour than in normal
mucosa. No significant difference was observed between
primary tumours and lymph node metastases. As shown in
Table III the level of c-Ha-ras RNA expression was not
influenced by the state of c-Ha-ras gene in tumours (loss of
allele, mutation, or presence of rare allele).c-Ha-ras IN HEAD AND NECK SQUAMOUS CELL CARCINOMAS
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Figure 4 Allelic deletions on chromosome lIp in head and neck carcinomas. Southern blot hybridisation, DNA from normal
mucosa (N) and primary tumour (T) of a head and neck patient with a larynx location (Patient d Figure 5). Restriction enzymes
used were HpaII/MspI for c-Ha-ras and DlI S12 loci, HindIII for HBBC, PstI for parathyroid hormone (PTH) locus and TaqI for
calcitonin (CALC) and catalase (CAT) loci. Allelic deletions were observed for HBBC and CALC, the presence of a faint 8 kb
hybridisation band was due to the presence of normal cells in these tumours. Only sizes in kb of DNA bands which could undergo
an allele loss are given.
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Figure 5 Map of the common region of llp deletion. Positions
of 6 genes or markers from chromosome lI p are shown, a black
box indicates that I parental allele was lost in the carcinoma, a
hatched box indicates that both parental alleles were retained in
the carcinoma, an open box indicates that the marker was not
informative (the patient's normal mucosa was homozygous for
the marker). An allele loss (apolipoprotein l, Apo Al) on
chromosome lq is also shown.
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Figure 7 Analysis of DNA and total RNA prepared from the
same specimens of head and neck carcinoma for amplification
and expression of the c-Ha-ras gene. EJ, cell line; Ca, carcinoma;
N, normal mucosa. A, Southern blot analysis: DNA (5 ILg per
well) was incubated with Sac! restriction endonculease. B,
Northern blot analysis of total RNA (10 lg per well). Filters
were sequentially hybridised with the c-Ha-ras probe then actin
probe; kb, kilobase pair, c-Ha-ras-I probe 2 (Figure 2).
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Figure 6 Dot hybridisation of in vitro-amplification DNA by
PCR from head and neck carcinoma and EJ cells with oligomer
probes corresponding to Gly (wild type) and Val of c-Ha-ras
codon 12. Only 2 mutations (lanes lA and IC) affecting Ha-ras
were observed in carcinomas and in EJ cells (lane 7B).
Figure 8 Analysis of c-Ha-ras transcripts by slot blot hybridisa-
tion (5 ltg of total RNA in each slot). Filters were sequentially
hybridised with the c-Ha-ras-l probe (probe 2 of Figure 2) and
the actin probe. Panels A, B, C lanes to 10, RNA from head
and neck carcinoma except in B lane 10, RNA from EJ cell line.
Panel D, lanes 1-2, 3-4 and 5-6, carcinoma lymph-node metas-
tasis and lanes 7-8 and 9-10, primary tumour-normal mucosa
pairs from the same patients.
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Figure 9 Expression ofc-Ha-ras proto-oncogene in 60 specimens
of lymph node metastases (M) and 19 specimens of primary
tumours (T) from head and neck carcinomas of various locations
(see Table I) (at the top of each column, the number of car-
cinomas per group). The level of c-Ha-ras transcripts in each
carcinoma was evaluated relatively to the level found in EJ cells
(I unit). The values were measured by densitometer analysis
(Chromoscan 3, Joyce Loebl) of slot blot autoradiograms (see
Figure 8). Controls for amount of total RNA in each slot were
provided by actin signal, considering that actin mRNA levels did
not vary in carcinomas.
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Figure 10 Relative levels of c-Ha-ras expression in pairs primary
tumour (T, black stripe)-normal mucosa (N, white stripe) and
pairs primary tumour (black stripe)-lymph node metastasis (M,
cross-hatched stripe). For quantitation see legend of Figure 8 and
Materials and methods.
Table III Expression of the c-Ha-ras gene according to its
structural characteristics
Characteristics
of c-Ha-ras in Relative level
individual carcinomas of c-Ha-ras mRNA
Allelic deletion
0138a 0.39
02 0.42
042 0.62
055 0.69
08 0.85
033 2
0140 3.4
Mutation at codon 12
052 0.38
050 0.54
Rares alleles
022 0.4
037 0.69
04 0.92
0,4 1.2
060 1.3
apatient no.
Discussion
Head and neck cancers are among the commonest cancers
world-wide (Parkin et al., 1984) and the large geographical
variations in incidence have suggested the importance of
environmental risk factors (Blot et al., 1988; Tuyns et al.,
1988). Epidemiological studies have shown that these cancers,
if we except carcinomas of the nasopharynx for which
Epstein-Barr virus is the main aetiological factor, were
strongly associated with a high intake of alcohol and tobacco
smoking. The majority of carcinomas of this study developed
in patients with poor prognosis since specimens were
obtained from lymph node metastases exhibiting extracap-
sular rupture (Table I, Figure lc).
Studies have reported that an aberrant expression of the
c-Ha-ras gene was associated with tumoral progression (Viola
et al., 1986; Clair et al., 1987; Spandidos et al., 1985; Azuma
et al., 1987). If the c-Ha-ras gene was involved in head and
neck tumour progression, we should expect to find c-Ha-ras
gene alteration or overexpression with a high frequency in
these very aggressive cancers. We have analysed the c-Ha-ras-
1 RFLP for HpaII-MspI enzymes in these carcinomas com-
paratively to a control population of healthy blood donors
and found no significant differences in the alleles frequencies.
Consequently, the presence of variant alleles at the c-Ha-ras-
I locus does not seem to be an informative marker for the
genetic predisposition to head and neck carcinomas, as has
been suggested in cancers of other origins (Krontiris et al.,
1985).
Recent studies have shown that allelic deletions could sig-
nal the presence of a tumour suppressor gene within the
affected regions of the chromosome. When both allelic copies
of such a gene are inactivated, suppression may be relieved
resulting in an abnormal proliferation. This process was par-
ticularly well documented for retinoblastoma and Wilm's
tumour, 2 childhood tumours (Knudson, 1987; Friend et al.,
1988). The tumour suppressor gene concept was extended to
other common adult malignancies but the numerous studies
undertaken until now have still not clearly shown the
involvement of such suppressor genes. Rather, these studies
have reported chromosomal deletions affecting particular loci
in certain carcinomas, suggesting a prevalent role of these
alterations in the development of malignanies Deletions on
the short arm of chromosome 11 were consider as being a
common and important event in the development of many
cancers and sometimes in tumour progreson. Of the 46
head and neck carcinomas whose patients were constitu-
tionally heterozygous for the c-Ha-ras locus, the loss of I
allele was detected in 10 (22%) specimens. The deletions were
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all found in the lymph node metastases exhibiting an extra-
capsular rupture (Figure Ic), and not detected in the 9
primary tumours from patients with negative nodes.
Although this observation was in favour of a role of the
c-Ha-ras allelic deletion in head and neck tumour progres-
sion, no definitive conclusion can be drawn because of the
small number of tumours examined (Exact Fisher test,
P = 0.29). Deletions of HBBC genes located on the short
arm of chromosome 11 were also found in 4 of 11 car-
cinomas. These deletions were accompanied with the loss of I
c-Ha-ras allele in 3 tumours and with the loss of I calcitonin
allele in 1 tumour (Figures 4 and 5). This result confirms
recent data obtained in breast carcinoma showing that, the
most frequent loss of sequences occur between the P globin
and parathyroid hormone loci on the short arm of
chromosome 11 (Ali et al., 1987).
Using the PCR technique and hybridisation with specific
oligonucleotide probes our present data showed that muta-
tions on the c-Ha-ras locus were not frequent in head and
neck carcinomas since, of the 54 DNA preparations
analysed, only 2 mutations were detected on codon 12 in-
volving a G T transversion. These mutations were somatic
since not observed in the constitutional DNA from patient
lymphocytes. Mutations on the c-Ha-ras locus are not fre-
quently found in human cancers, however, in a series of 76
invasive squamous cell carcinomas of the uterine cervix,
mutations involving codon 12 were found to be significantly
(P <0.01) associated with advanced stages of the disease
Riou et al. (1988). No mutations were found in any of the
codons 12, 13 and 61 of the c-Ki-ras and of the codons 12
and 61 of the N-ras (data not shown).
It is now well established that amplification of proto-
oncogenes is a late event associated with advanced stages of
the disease in some types of invasive cancers. This is the case
for example of the myc gene family and of the c-erbB2 gene.
The c-myc gene was found to be amplified in advanced stages
of cervical carcinomas (Riou et al., 1984; Riou, 1988; Ocadiz
et al., 1987) and the N-myc gene in advanced stages of
neuroblastomas (Seeger et al., 1985; Bourhis et al., 1989).
The c-erbB2 gene was also detected in a relatively high
proportion of breast carcinomas of poor prognosis as are
those with multiple lymph node involvement (Slamon et al.,
1987; Guerin et al., 1988; Guerin et al., 1989a) and
inflammatory breast cancers (Guerin et al., 1989b). To our
knowledge, very few data have reported a c-Ha-ras gene
amplification in fresh human cancers. Using the 6.6kb
BamH1 DNA restriction fragment as a probe, an
amplification was observed in a limited series of cervical
cancers of stages III and IV (Riou et al., 1985). In the
present study, Southern blot analysis performed in the 81
DNA preparations from head and neck carcinomas did not
reveal the presence ofeither amplification or gross rearrange-
ment of the c-Ha-ras locus.
It is known that aberrant expression of ras oncogene,
either at the qualitative or quantitative levels, can result in
malignant transformation and/or differentiation (Barbacid,
1988). Immunohistochemistry studies performed in ultrathin
sections in a variety oftumours have reported the presence of
the p21 ras protein in higher concentration in the tumoral
tissues than in the peripheral non-tumoral tissues (Barbacid,
1988; Viola et al., 1986; Clair et al., 1987). These data
suggested that overexpression was associated with progres-
sion of the tumour and thus with a poor clinical prognosis.
However some recent studies are controversial and support
the findings that elevation of the p21 may be a common
event in early stages of tumours, which is not related to the
proliferative activity of a variety of human malignancies
(Spandidos & Kerr, 1984; Gallick et al., 1985; Chesa et al.,
1987). Furthermore, in neuroblastomas the c-Ha-ras protein
expression was correlated with a favourable prognosis and
early stage of disease (Tanaka et al., 1988). These data
suggest that the c-Ha-ras gene product may play a role in
decreasing the aggressiveness of neuroblastoma cells in vivo
and may be related to cellular differentiation.
In the present study, we show that, in head and neck
carcinomas, a transcript band displaying different degree of
hybridisation intensity was observed in primary tumours as
well as in lymph node metastases. The relative levels of
transcripts were not found to be significantly different in
primary tumours and in lymph node metastases although the
latter specimens were obtained from nodes with extracapsular
rupture, one of the most powerful indicator of poor prog-
nosis in these types of carcinomas. The transcript levels were
not found to be significantly higher in primary tumours than
in adjacent normal mucosa with the exception of 2 cases
(Figure 10). Mucosa obtained at surgery were composed of
normal cells as shown by histopathological examination.
They were used as tissue controls allowing the detection of
c-Ha-ras deletion (2 cases) and HBBC (1 case) deletions
(Figures 3 and 4).
In conclusion, our data showed that the c-Ha-ras tran-
scription does not seem to be a major event in the tumour
progression of head and neck squamous cell carcinoma, as
has been reported in other tumour types. It is quite possible
that increase of c-Ha-ras transcripts and/or protein was
important for the initiation step of head and neck car-
cinogenesis (Field et al., 1986) but that in later steps other
genes may supplant the role of this gene.
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